No abstract

steroidal anti-inflammatory drug (NSAID) of the coxib class, intended for the treatment of pain and inflammation associated with osteoarthritis in dogs (VMD, 2021) that shows potent anti-inflammatory and analgesic activities when tested in experimental models of inflammation and pain (Wagemakers et al., 2009). Its chemical name is 4-(5-(2,4-difluorophenyl)-3-(trifluoromethyl)-4,5-dihydro-1H-pyr azol-1-yl) benzenesulfonamide (C 16 H 12 F 5 N 3 O 2 S, Figure 1). After oral administration to dogs, it is readily absorbed and undergoes extensive hepatic metabolism forming two main phase I metabolites, a hydroxylated pyrazoline and a pyrazol derivative. Both enflicoxib and its pyrazol metabolite are potent inhibitors of the COX-2 enzymatic activity

Background: Enflicoxib is a new COX-2 selective NSAID intended for the treatment of pain and inflammation associated with canine osteoarthritis. Methods: A prospective, multisite, blinded, randomised, controlled, parallelgroup field study was performed to determine the efficacy and safety of enflicoxib in canine osteoarthritis. A total of 242 dogs were randomised to receive enflicoxib at 4 or 2 mg/kg, mavacoxib at 2 mg/kg or placebo, orally. Enflicoxib and placebo were administered once weekly from day 0 to day 35. Mavacoxib was administered on D0 and day 14. Veterinarians assessed efficacy with a numerical rating scale and owners used the Canine Brief Pain Inventory. Results: After 6 weeks, enflicoxib at 4 mg/kg showed the highest percentage of responders as assessed by the veterinarians (68%) and the owners (84%), followed by mavacoxib (62and 83%, respectively), and enflicoxib at 2 mg/kg (57 and 80%, respectively). All treatments reached statistical significance versus placebo, which obtained success rates of 37% and 53%, respectively. No differences in the incidence of adverse reactions were detected among the different groups. Conclusions: Enflicoxib administered weekly for 6 weeks, at 4 mg/kg PO with an initial loading dose of 8 mg/kg, is efficacious and safe for the treatment of canine osteoarthritis.

SBZ is a good therapeutic alternative to PBZ in horses since there is no significant difference in alleviating lameness between the 2 therapies.

No abstract